Information date: 3 September 2026 — Peptide skincare marketing often compresses cell studies, animal models, formulation tests and human outcomes into one claim. A small randomized study of a topical GHK-Cu regimen after carbon-dioxide laser resurfacing shows why those layers must stay separate: subjective satisfaction and objective measurements did not tell the same story.
Verified facts and scope
The 2006 study indexed at PubMed randomized patients after circumoral carbon-dioxide laser resurfacing to post-procedure regimens with or without a copper tripeptide complex. Thirteen participants completed the study. Computer analysis and blinded evaluators did not find a significant between-group difference in erythema resolution, wrinkles or overall skin appearance, while a patient questionnaire favored the copper-peptide regimen for perceived overall skin quality.
This was a topical post-procedure setting, not an evaluation of injected GHK-Cu, systemic anti-aging, routine use on intact skin or disease treatment. A sample of thirteen offers limited precision, and one favorable subjective outcome cannot erase null objective outcomes. It can generate a testable hypothesis, not a broad efficacy guarantee.
How the effect reaches operations
A mechanism observed in cells may explain biological plausibility but does not establish that a finished formula reaches the relevant tissue or improves a patient-important outcome.
A formula contains vehicles, preservatives and other actives, so a regimen result cannot automatically be assigned to one peptide.
Post-laser skin has a different barrier and clinical context from ordinary cosmetic use, which limits direct generalization.
Decision
Publish a skincare claim only at the level supported by the study design. Describe the product, route, population, comparator, duration and measured endpoint. When objective and subjective outcomes diverge, report both. Do not convert a topical cosmetic study into support for injection, healing a medical condition or whole-body anti-aging.
Implementation checklist
- Classify every cited source as laboratory, animal, observational human, randomized human or systematic review evidence.
- Record the exact formulation, route, comparator, sample size, completion count, duration and endpoint.
- Separate instrument measurements, blinded assessments and participant-reported outcomes in the evidence table.
- Check whether the marketed population and use setting match the study population and procedure.
- Rewrite each claim to the narrowest result that remains true without omitting a material null finding.
- Set a review date and replace the claim only when stronger direct human evidence becomes available.
Evidence and review
For “Peptide Skincare Claims Need an Evidence Ladder: What a 13-Person GHK-Cu Trial Can and Cannot Show”, start with one real case rather than an abstract checklist. Record the input version, responsible owner, start time, observed result and stop condition. If the team cannot complete “Classify every cited source as laboratory, animal, observational human, randomized human or systematic review evidence.” with current evidence, it should not expand the process to more products, patients, suppliers or markets. The first review should focus only on facts capable of changing the decision.
The second control follows “Record the exact formulation, route, comparator, sample size, completion count, duration and endpoint.”. Keep the source date, applicable population or entity, deadline, cost effect and owner in the same evidence file. A wording preference does not justify a new version. A repeated discrepancy, an unsupported health claim or a regulatory mismatch does: correct that point and hold release until the evidence is available.
After “Separate instrument measurements, blinded assessments and participant-reported outcomes in the evidence table.”, compare the intended outcome with what actually happened. Apply the same success criteria to each later expansion. If only one number, date or responsibility changes, update that field and the affected conclusion instead of recreating evidence that remains valid. This keeps the decision traceable without turning review into an open-ended rewrite cycle.
Release criterion
The release test for “Peptide Skincare Claims Need an Evidence Ladder: What a 13-Person GHK-Cu Trial Can and Cannot Show” is not document volume. Each material number needs a date and denominator, each action needs an owner and trigger, and each exception needs an escalation route. When the source, operating step and limit align, minor wording differences do not justify another rewrite. If the conclusion still depends on an unverified assumption, narrow the claim or pause the affected decision until direct evidence is available.
Limits of the conclusion
This article is an evidence-reading exercise, not a recommendation to use a peptide product. It provides no diagnosis, treatment, application, injection, reconstitution or dosing instructions. People considering post-procedure skincare should follow the clinician responsible for their care and the authorized product information.
